Market news

CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Cantor 2026 Global Healthcare Conference in New York City on Thursday, September 10, 2026 at 9:45 a.m. ET. A live webcast of the present

Wave Life Sciences has lost nearly 70% of its value this year, yet its RNA platform spans obesity, rare liver disease, and genetic disorders in ways that could make it irresistible to the right buyer. The question is which pharma giant moves first.

Wave Life Sciences (WVE) stock analysis: low valuation (2.45x cash, no debt) vs. RNA therapy competition; key upside tied to WVE-N531 results. See more here.

CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“Wave” or “Wave Life Sciences”), has obtained the requisite shareholder approvals required in connection with its proposed redomiciliation (“Redomiciliation”) to the United States by way of the implementation of a statutory procedure known as a scheme of arran

CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that members of Wave’s management team are scheduled to participate in two upcoming investor conferences in August. BofA Securities 2026 SMID Cap Executive Insights EventDate: Tuesday, August 11, 2026 Details: Paul Bolno, MD, MBA, President and CEO, will participate in

Detailed price information for Wave Life Sciences Inc (WVE-Q) from The Globe and Mail including charting and trades.

WVE-007 obesity candidate shows 16.5% visceral fat improvement in early trials.

Detailed price information for Wave Life Sciences Inc (WVE-Q) from The Globe and Mail including charting and trades.

Wave Life Sciences (WVE) has an average rating of Buy and mean price target of $28, according to ana

WAVE Life Sciences reports robust data for obesity candidate WVE-007 and AATD therapy WVE-006, while navigating a wider net loss and declining revenue.

WAVE Life Sciences (NASDAQ:WVE) reported a wider second-quarter loss as it increased investment in its obesity and RNA-editing programs, while outlining several clinical and regulatory milestones expected in the second half of 2026. The company reported second-quarter revenue of $2.3 million, down

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -9.68% and -73.48%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Wave Life Sciences (WVE) shares fell 2.9% in Thursday trading after the company reported a wider Q2

Moby summary of Wave Life Sciences Ltd.'s Q2 2026 earnings call

Dosing underway in Phase 2a multidose portion of the INLIGHTTM trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with obesity (BMI: 35-50 kg/m2) and comorbidities; trial will also inform WVE-007's potential in MASH, type 2 diabetes, and other cardiometabolic diseases Phase 2 combination with incretin and post-incretin maintenance trials of WVE-007 on track to initiate in 2H 2026 FDA meeting scheduled for end of summer 2026 on potential accelerated approval pathway for WVE-006 (GalNAc-RNA edit

Wave Life Sciences has seen its share price fall 64.0% year to date, yet the valuation checks suggest the stock still screens as expensive rather than a clear bargain. Wave Life Sciences is down 64.0% year to date, which puts the recent slide front and center for anyone weighing the current valuation. Future progress on its drug pipeline can support the case for the current price, while uncertainty around the timing and reliability of cash flows remains a key risk for how much investors are...

CAMBRIDGE, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, July 30, 2026, to review the company’s second quarter 2026 financial results and provide business updates. The webcast and conference call may be accessed by visiting “Investor Events” on the investors section o

Wave Life Sciences (WVE) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“Wave” or “Wave Life Sciences”), has obtained the requisite shareholder approval required in connection with its proposed redomiciliation (“Redomiciliation”) to the United States by way of the implementation of a statutory procedure known as a scheme of arrang